April 26-29, 2027 | Hynes Convention Center, Boston, MA

TIDES Oligonucleotide & Peptide Therapeutics by informa USA

Preliminary Agenda

(Confirmed & Invited Speakers as of September 19, 2026)



Patrick C. Reid, PhD
President and CEO
PeptiDream, Inc.



John Maraganore, PhD
Founding CEO, Alnylam & CEO and Principal
JMM Innovations, LLC



Jane Grogan, PhD
Executive Vice President & Head of Research
Biogen



Kristy Wood, PhD
Senior Vice President, Technical Operations
Intellia Therapeutics

...and many more!

Register by Dec 11 & Save $1200

***PLEASE NOTE:** The TIDES Registration fee increases every month leading up to the conference dates, so the earlier you register the more you save. Our first registration price increase is THIS Friday, October 23 – so if you register this week, you will receive the lowest rate we will ever offer to attend TIDES 2027. Please share this information with the person at your company who handles conference attendance and get your whole team registered today!*

TIDES Oligonucleotide & Peptide Therapeutics by informa

USA

Pre-Conference Workshops & Keynotes

Monday, April 26, 2027 | 9:00am - 5:00pm

PRE-CONFERENCE WORKSHOPS

Morning Workshops (Choose One)

Workshop AM1: Introduction to Therapeutic Oligonucleotides - Design, Function and Delivery
Workshop Leader:
Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharm

Workshop AM2: Navigating Comparability Through Late-Stage Process Changes in Synthetic Oligonucleotides
Workshop Leaders:
Fran Wincott, Ph.D., President, Wincott & Associates, LLC
Lori Troup, Senior Director, Analytical Development, Novo Nordisk

Workshop AM3: In Vivo CAR-T & In Vivo Genome Editing: Delivering the Payload
Workshop Leaders:
John Zuris, Ph.D., Principal, John Zuris Consulting LLC
Steven Wolk, Ph.D., Founder and Chief Consultant, Sinawali Biotechnology Solutions

Workshop AM4: Peptide Synthesis: Disruptive Strategies & Technologies
Workshop Leader:
Fernando Albericio, Ph.D., Research Professor, School of Chemistry, University of Kwazulu-Natal, South Africa

PRE-CONFERENCE WORKSHOPS

Afternoon Workshops (Choose One)

Workshop PM1: CMC Strategies for a Phase 1 Oligonucleotide IND
Workshop Leader: Kathryn L. Ackley, Ph.D., CMC Consultant Specializing in Oligonucleotides

Workshop PM2: Introduction to Analytical Control Strategies for Therapeutic Oligonucleotides
Workshop Leader: Mike Webb, Ph.D., Founder and CEO, Mike Webb Pharma

Workshop PM3: Challenges and Opportunities in Oligonucleotide Quality Control: From Development to Commercial Supply
Workshop Leader TBA

Workshop PM4: De-Risking CMC for Complex & Macrocyclic Peptides and the Oral Delivery Challenge
Workshop Leader: Matteo Villain, Ph.D., Vice President of Peptides and Oligonucleotides, Veranova

TIDES Oligonucleotide & Peptide Therapeutics by informa

USA

Main Conference
April 27-29, 2027

Confirmed Keynote Speakers

Progress in the Treatment of CNS Disease Using "TIDES" Conjugates and Diverse Modalities
Jane Grogan, Ph.D., Executive Vice President & Head of Research
Biogen

Realizing the Power and Promise of Macrocyclic Peptides
Patrick C. Reid, Ph.D., President and CEO
PeptiDream, Inc., Japan

The Next Frontier for RNA Therapeutics – Emerging Applications, Opportunities and Recent Successes
John Maraganore, Ph.D., Founding CEO, Alnylam Pharmaceuticals
CEO and Principal, JMM Innovations, LLC

Directed Evolution for the Development of Next-Generation Peptide Therapeutics
Tina Boville, Ph.D., CEO
Aralez Bio

Analytical and Process Control Strategies for Next-Generation Oligonucleotides
Todd Maloney, Ph.D., Associate Vice President
Eli Lilly & Company

The Path to the Clinic and to Market for Lonvo-z: An in vivo CRISPR Gene-editing Therapy Administered Directly Inside the Body
Kristy Wood, Ph.D., SVP, Technical Operations
Intellia Therapeutics

TIDES Oligonucleotide & Peptide Therapeutics by informa

USA

Main Conference

April 27-29, 2027

Oligonucleotide Speakers

(SESSION) Emergence of Continuous Flow Chemistry for "TIDES" Manufacturing
Session Chair: Yogesh Sanghvi, Ph.D., President, Rasayan, Inc.

Transforming Oligonucleotide Manufacturing Through Continuous Processing
Roman Hillebrand, Ph.D., Co-founder and CTO/COO, OligoStream Industries

Advances in Continuous Flow Chemistry for Oligo Manufacturing
Caleb Culy, Senior Principal Chemist, Process Design and Development, Eli Lilly and Company (Invited)

Continuous Flow Chemistry Technology and Applications
Yannick Fillon, Ph.D., Product Technical Lead, Oligonucleotides, Biogen (Invited)

Novel Chemistries for "TIDES" Manufacturing
Kurt Vagle, Senior Director, Chemical Development RNAi, Novo Nordisk (Invited)

Emerging Applications of Continuous Flow Chemistry
Romain Morodo, Ph.D., Senior Scientist, Process Chemistry, CatSci Ltd., United Kingdom (Invited)

(SESSION) Analytical and Regulatory CMC Strategies for Oligonucleotides
Session Chair: Carolyn Mazzitelli, Ph.D., Executive Director, Ionis Pharmaceuticals

(SESSION) Innovations in Oligonucleotide CMC
Chair: Li Xiao, Ph.D., Director, Synthetic Molecule Design & Development, Eli Lilly and Company

guide RNA Development, Analytics and CMC
Rowshon Alam, Ph.D., Vice President, Head of Chemistry, Prime Medicine

Regulatory Strategies for Oligonucleotide Therapeutics
Maged Darwish, Ph.D., Vice President, Global Regulatory Affairs, CMC, Alnylam Pharmaceuticals

CMC Strategies for gRNA
Eric Tillotson, Scientist, Verve Therapeutics/Eli Lilly (Invited)

CMC Strategies for Stereochemistry from the EPOC Stereochemistry Working Group
Speaker TBA

Advancement of Kidney-directed siRNAs to the Clinic
William Kiesman, Ph.D., Chief Technology Officer, Judo Bio

Advancing ARO-MAPT-SC, a Shuttled RNAi Therapeutic, in the Clinic for the Treatment of Alzheimer's Disease
Roger Chang, M.D., Ph.D., Associate Medical Director, Arrowhead Pharmaceuticals

Oligonucleotide Speakers (continued)

Safety, Tolerability and Preliminary Efficacy of Domusiran, a JAK1-Targeting siRNA, Following Intralesional Administration in Patients with Alopecia Areata: Results from a Phase IIa Study
Carine Blanchard, Ph.D., Chief Scientific Officer, Aldena Therapeutics

Next-generation siRNA Therapeutics
Robert MacLeod, Chief Scientific Officer, ADARx Pharmaceuticals (Invited)

(SESSION) Oligonucleotide Discovery and Chemistry
Session Chair: Troels Koch, Ph.D., Chief Technology Officer, Cora Biosciences

Oligo Chemistry and Conjugation Strategies in Alnylam Programs
Jayaprakash Nair, Ph.D., VP, Research, Chemistry and Delivery Science, Alnylam Pharmaceuticals

RNA Goes South: Advances in RNAi Chemistry for Extra-hepatic Applications
Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Innovation and Distinguished Research Scientist, Alnylam Pharmaceuticals

(SESSION) Oligonucleotide Chemistry and Bioconjugation Strategies for Extrahepatic Delivery
Session Chair: Rubina Parmar, Ph.D., Senior Vice President, Head of Technology, Atlas Venture NewCo

Conjugate Strategies for Systemic CNS Delivery of Oligonucleotide Therapeutics
Ian Huggins, Ph.D., Senior Director, Delivery Services, Aerska

Considerations for Oligonucleotide Delivery to Muscle and CNS Using the FORCE Platform
Saul Martinez Montero, Ph.D., Executive Director, RNA Therapeutics, Dyne Therapeutics

Brain Delivery Platform Technology
Tao Pei, Ph.D., Chief Scientific Officer, Arrowhead Pharmaceuticals

Oligonucleotide Speakers (continuted)

Precision Oligonucleotide Therapies
Vadim Dudkin, Ph.D., Founding Chief Technology Officer, Souffle Therapeutics (Invited)

Oligonucleotide Chemistry and Conjugation Strategies
Anastasia Khvorova, Ph.D., Professor, RNA Therapeutics Institute, UMass Chan Medical School (Invited)

(SESSION) The Intersection of AI and RNA Technologies to Accelerate Drug Discovery and Development
Session Chair: Seth Alexander, Ph.D., Director, Enterprise AI, Prime Medicine

AI in mRNA and tLNPs: Reality vs. Hype
Devan Shah, Founder & Chief Executive Officer, RNAV8 Bio

AI for Therapeutic Design: Applications in Genome Editing, RNA or "TIDES" Related Drug Modalities
John Finn, Ph.D., Chief Scientific Officer, Basecamp Research

AI Technology and Application in Therapeutic Development
Nick Perry, Scientist, Anthropic (Invited)

AI Applications in Drug Discovery and Development
Thomas Fuchs, Chief AI Officer, Eli Lilly & Company (Invited)

Integrating AI into Drug Discovery and Drug Development Pipelines
Kathryn Petrini, Scientist, Google (Invited)

Advances in AI Application for Pharmaceutical and Biotech R&D
Dimitri Maltezakis Vathypetrou, Scientist, Nvidia (Invited)

(SESSION) "TIDES" Conjugates: Merging Modalities for Novel Therapeutics
Session Chair: Kevin P. Cole Ph.D., Executive Director, Bioproduct Research and Development, Lilly Research Laboratories

Antibody-Oligonucleotide Conjugates
Mike Martini, Scientist, Avidity Biosciences (Invited)

Oligonucleotide Speakers (continuted)

CMC Strategies for AOC's
Nicolas Cuniere, Science, Bristol-Myers Squibb (Invited)

Peptide-Fc Conjugates
Paul Bulger, Scientist, Merck (Invited)

Conjugation Strategies for Antibody-Oligo Conjugations
Naim Nazef, Scientist, Denali Therapeutics (Invited)

Lessons Learned from Maritide, An Antibody-peptide Conjugate
Andrew Parsons, Scientist, Amgen (Invited)

(SESSION) Multimeric and Multivalent Oligonucleotides
Session Chair: TBA

Progress of Alnylam's Gemini Platform for the Development of Multimeric Oligonucleotides
Ivan Zlatev, Ph.D., Executive Director of Research, Alnylam Pharmaceuticals

Overcoming Scale-Up Barriers: Ensuring Robust CMC for Next-Gen Peptide and Oligonucleotide Drugs
William Fang, Vice President of Oligonucleotide and Peptide Development, WuXi TIDES

From Synthesis to Purification: Resin Design Across the Peptide and Oligonucleotide Workflow
Simona Serban, Ph.D., Global Applications Director, Life Sciences, Sunresin

TIDES Oligonucleotide & Peptide Therapeutics by informa

USA

Main Conference

April 27-29, 2027

Peptide Speakers

Continuous N-to-C Peptide Synthesis: A New Platform for Sustainable Peptide Manufacturing
Kaijiong Xiao, Ph.D., Principal Scientist, Process Research & Development, Merck & Co.

Scaling a Helicon Peptide: Manufacturing Process Development for Zolucatetide
Tomer Faraggi, Ph.D., Senior Scientist, Parabilis Medicines

(SESSION) Beyond GLP1: The Next-Generation of Peptide Therapeutics
Session Chair: Florence Brunel, Ph.D., Scientific Chemical Biology Director, Novo Nordisk

Peptide Quintuple Agonists for the Treatment of Obesity and Type 2 Diabetes
Patrick Knerr, Ph.D., Vice President, Metabolic Translational Research, Indiana Biosciences Research Institute

Oral Peptide Therapeutics
Thomas Eiland, Scientist, Novo Nordisk, Denmark

Peptides in Modern Drug Discovery: A Modality Coming of Age
Ranganath Gopalakrishnan, Ph.D., Senior Director and Senior Principal Scientist, Zealand Pharma, Denmark

Beyond Weight Loss: Improving Body Composition with Long-acting GUB-UCN2
Louise Dalboge, Ph.D., Chief Scientific Officer, Gubra Biotech, Denmark

Triple Combinations
Brian Finan, Ph.D., Associate Vice President - Obesity & Metabolic Research, Eli Lilly & Company (Invited)

Advances in Peptide Discovery and Development
Hannah Bolt, Ph.D., Head of Peptide Discovery, AstraZeneca, United Kingdom (Invited)

(SESSION) Innovations in Peptide Discovery and Development: Applications for Novel Therapeutics
Session Chair: David Craik, Ph.D., Professor of Biomolecular Structure, Institute for Molecular Bioscience, University of Queensland, Australia

Peptide Speakers (continued)

Discovery and Preclinical Development of Peptide Targeting Agents
Ratmir Derda, Ph.D., Founder and CSO, 48 Hour Discovery and Associate Professor, Department of Chemistry, University of Alberta

Synthesis of Peptides and Proteins by Native chemical Ligation
Phil Dawson, Professor, Scripps Research Institute (Invited)

Unlocking Macrocyclic Peptides for Challenging Drug Targets
Cameron Pye, Scientist, Unnatural Products (Invited)

(SESSION) Innovations in Peptide CMC
Session Chair: Marc Jacob, Ph.D., Head of Strategic Development, Chromatography Products, YMC America

Thyclotides that Deliver Peptides into Cells
Dan Appella, Ph.D., Senior Investigator, NIDDK, NIH

Advancing Sustainable API and Peptide Manufacturing Through Solvent Recovery
Matthew Whitten, Principal Engineer, Donaldson

An Integrated Control Strategy for Diastereomeric Impurities in Peptide APIs
Daphne Schaerlaeckens, Scientific Lab Technician, Aspen Oss, The Netherlands

Overcoming Scale-Up Barriers: Ensuring Robust CMC for Next-Gen Peptide and Oligonucleotide Drugs
William Fang, Vice President of Oligonucleotide and Peptide Development, WuXi TIDES

From Synthesis to Purification: Resin Design Across the Peptide and Oligonucleotide Workflow
Simona Serban, Ph.D., Global Applications Director, Life Sciences, Sunresin

Delivery and LNPs Speakers

(SESSION) Delivery Strategies to Muscle
Session Chair: Julia Alterman, Ph.D., Assistant Professor, RNA Therapeutics Institute, University of Massachusetts Chan Medical

(SESSION) Targeting Ligands for Extrahepatic Delivery of Genetic Cargoes
Session Chair: Luis Brito, Ph.D., Vice President, Delivery Platform, Beam Therapeutics

(SESSION) Beyond the Liver: Targeted Delivery of Oligonucleotides
Session Chair: Elissa Hobert, Ph.D., Senior Director of Discovery Technologies, Souffle Therapeutics

Delivery of siRNA to Kidneys and the Vascular System
Yaniv Erlich, Ph.D., CEO and Co-Founder, Undecimal Bio

Unique Receptor for Extrahepatic Delivery of Oligonucleotides
Thazha Prakash, Ph.D., Executive Research Fellow, Ionis Pharmaceuticals (Invited)

Targeting a Variety of Ligands for Oligonucleotide Delivery
Stephanie Malocco, Scientist, Evercrisp (Invited)

Oligonucleotide Chemistry and Conjugation Strategies
Michael Cochran, Ph.D., Director of Chemistry, Avidity Biosciences (Invited)

(SESSION) Adipose Oligonucleotide Delivery
Session Chair TBA

Peptide-siRNA Conjugates Enable Efficacious siRNA Delivery to Adipose Tissue via a Novel Targeting Receptor
Emma Kay, Ph.D., Associate Principal Scientist, Astra Zeneca, Sweden

LNP Process Development and Analytics for mRNA Vaccines and Targeted LNPs
Andreas Wagner, Ph.D., Head of Liposome Technology, Polymun Scientific GmbH, Austria

TIDES Oligonucleotide & Peptide Therapeutics by informa

USA

Main Conference

April 27-29, 2027

Genome Editing & mRNA Speakers

Prime Editing in the Context of Genome Editing Developments and Updates from Prime Medicine
Andrew Anzalone, M.D., Ph.D., Co-Founder and Head of Platform, Prime Medicine

Novel mRNA Cancer Therapies
Raquel Deering, Ph.D., Executive Director, Cancer Vaccine Research, Moderna

Panel Discussion: The Future of mRNA Vaccines for Oncology
Panel Chair: Gad Berdugo, Managing Partner, Explorium Capital LLC (Invited)

Moderna-Merck story – Personalized mRNA Vaccine
Rose Loughlin, EVP of Research and Technical Development, Moderna (Invited)

LNP Process Development and Analytics for mRNA Vaccines and Targeted LNPs
Andreas Wagner, Ph.D., Head of Liposome Technology, Polymun Scientific GmbH, Austria

New Post-Conference Workshop: Obesity Science & Innovation Workshop

The convergence of advanced therapeutic modalities and metabolic health innovation is reshaping drug development. From oligonucleotide-based RNA therapies to GLP-1 peptides, the technologies driving TIDES USA are directly enabling the obesity breakthroughs showcased at OSI.

Learn More about the OSI Workshop >

Want to be a Speaker?
For more information about being a speaker at this conference, contact Michael Keenan at Michael.Keenan@informa.com

Want to Exhibit or Sponsor?
Contact Jennifer Wickett: Jennifer.Wickett@informa.com